People who use drug Mounjaro can maintain weight loss for three years, according to the data of the test.
The MOUNJARO, nicknamed “King Kong” of the weight loss drug, contains a tir prepared fide and is self -managed once a week.
It mimics two hormones: GLP-1 and GIP, which inhibits appetite, increased insulin production, larger insulin sensitivity, and reduction in the speed ate from the stomach. The drug can be weight loss from some of the NHS and can be purchased personally by prescription.
Scientists from ELI Lilly, a company that creates Mounjaro with academia researchers, published two data analysis in three-year test known as Surmount-1, and presented fresh light for the long-term use of the drug. One analysis saw the trajectory of weight loss, and the second rebounded after the initial weight loss.
The results of the European Parliament on Malaga’s obesity next month are based on the data of about 700 participants who have taken Tirzepatide in three different dose therapies during the 176 weeks studies. All were obese or overweight and there was a diabetes war.
The results showed that the participants’ experiences followed that one of the three patterns, normal, medium or fast weight loss, and highlands, and later, the faster the initial decline. The team said the final average weight loss of the group was 9.2%, 20.2%and 30.8%, respectively. Each group included about one third of the participants.
Professor Luca Busetto, one of the first scientists of the first analysis, said, “(Work) shows that the weight loss speed observed during the first month of treatment can predict the final weight loss in any way.
Researchers said most participants maintained clinically significant weight loss in the research process. This was supported by the second analysis, and the average time for the lowest weight was 22 months, and at this point, the participants lost 23.1%of their weight.
Nevertheless, despite some drugs, weight was restored, but participants lost 19.4%of their weight on average at the end of the research.
The team added that 70% of the participants have recovered less than 5% of their weight when they have the lowest point.
Naveed Sattar at the University of Glasgow, who is not involved in the exam, said that the discovery of other weight loss trajectory can help to show how much weight the individual can lose in the long run. “This will allow some individuals to guide you to consider new treatments in the future,” he said, “he said,” he said.
Dr. Simon Cork of Anglia Ruskin University showed that the long -term effect of Tir discipleship, which maintains weight loss, said, “I am interested in health institutions because the cost of treating obesity -related agreements rises every year.”
Cork also conflicts with long -term efficiency and safety research on these drugs, which is limited to use for up to two years.
The results of the survey have been announced that the advertising standards have been banned from drugs, medical product regulators, and general pharmaceutical councils that they have banned drugs for prescription drugs. This includes weight loss JABS such as Mounjaro, Wegovy and Saxenda.
Among other examples, the rules ensure the sponsorship of social media’s “Facebook, Instagram and Tiktok images or video advertisements”, Google or other search engines sponsorship search and influenza.
According to the Guardian survey, weight loss injections have previously been actively sold to British consumers through illegal promotions.
